Ubiquitin chain cleavage: CYLD at work

Trends in Biochemical Sciences

Volumn 35, Issue 7, 2010, Pages 392-399

  Massoumi, Ramin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETAL ASSOCIATED PROTEIN GLYCINE CONSERVED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN BCL 3; PROTEIN CYLD; STRESS ACTIVATED PROTEIN KINASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CYLD PROTEIN, HUMAN;

APOPTOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; DEUBIQUITINATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; UBIQUITINATION; METABOLISM; SIGNAL TRANSDUCTION;

HUMANS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

EID: 77954310807     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2010.02.007     Document Type: Review

References (71)

1. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev.. Biochem. 2001, 70:503-533.
2. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2001, 2:169-178.
3. Nijman S.M.B., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
4. Komander D., et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 2009, 10:466-473.
5. Komander D., et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol. Cell 2008, 29:451-464.
6. Steinmetz M.O., Akhmanova A. Capturing protein tails by CAP-Gly domains. Trends Biochem. Sci. 2008, 33:535-545.
7. Gao J.M., et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J. Biol. Chem. 2008, 283:8802-8809.
8. Wickström S.A., et al. CYLD negatively regulates cell cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010, 29:131-144.
9. Trompouki E., et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 2009, 11:469-476.
10. Aggarwal B.B. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756.
11. Saito K., et al. The CAP-Gly domain with the proline-rich of CYLD associates sequence in NEMO/IKK gamma. Structure 2004, 12:1719-1728.
12. Bignell G.R., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 2000, 25:160-165.
13. Trompouki E., et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappa B activation by TNFR family members. Nature 2003, 424:793-796.
14. Kovalenko A., et al. The tumour suppressor CYLD negatively regulates NF-kappa B signalling by deubiquitination. Nature 2003, 424:801-805.
15. Brummelkamp T.R., et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B. Nature 2003, 424:797-801.
16. Regamey A., et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappa B activation by tumor necrosis factor. J. Exp. Med. 2003, 198:1959-1964.
17. Guazzone V.A., et al. Cytokines and chemokines in testicular inflammation: A brief review. Microsc. Res. Tech. 2009, 72:620-628.
18. Delfino F., Walker W.H. Hormonal regulation of the NF-kappaB signaling pathway. Mol. Cell Endocrinol. 1999, 157:1-9.
19. Wright A., et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 2007, 13:705-716.
20. Reiley W., et al. Negative regulation of JNK signaling by the tumor suppressor CYLD. J. Biol. Chem. 2004, 279:55161-55167.
21. Zhang J., et al. Impaired regulation of NF-kappa B and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 2006, 116:3042-3049.
22. Tsichritzis T., et al. A Drosophila ortholog of the human cylindromatosis tumor suppressor gene regulates triglyceride content and antibacterial defense. Development 2007, 134:2605-2614.
23. Xue L., et al. Tumor suppressor CYLD regulates JNK-Induced cell death in Drosophila. Dev. Cell 2007, 13:446-454.
24. Wang M.C., et al. JNK signaling confers tolerance to oxidative stress and extends lifespan in Drosophila. Dev. Cell 2003, 5:811-816.
25. Mckeithan T.W., et al. Identification of a transcriptional unit adjacent to the breakpoint in the 14-19 translocation of chronic lymphocytic-leukemia. Genes Chromosomes Cancer 1990, 1:247-255.
26. Cogswell P.C., et al. Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000, 19:1123-1131.
27. Thornburg N.J., et al. Activation of nuclear factor-kappa B p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003, 63:8293-8301.
28. Budunova I.V., et al. Increased expression of p50-NF-kappa B and constitutive activation of NF-kappa B transcription factors during mouse skin carcinogenesis. Oncogene 1999, 18:7423-7431.
29. Massoumi R., et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 2009, 206:221-232.
30. Park S.G., et al. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J. Biol. Chem. 2006, 281:31770-31777.
31. Massoumi R., et al. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappa B signaling. Cell 2006, 125:665-677.
32. Uffort D.G., et al. NF-kappa B mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J. Invest. Dermatol. 2009, 129:148-154.
33. Takami Y., et al. Potential role of CYLD (cylindromatosis) as a deubiquitinating enzyme in vascular cells. Am. J. Pathol. 2008, 172:818-829.
34. Stegmeier F., et al. The tumor suppressor CYLD regulates entry into mitosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8869-8874.
35. Takaki T., et al. Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 2008, 20:650-660.
36. Wang L., et al. The BRG1-and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol. Cell Biol. 2005, 25:7953-7965.
37. Jono H., et al. NF-kappa B is essential for induction of CYLD, the negative regulator of NF-kappa B - Evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem. 2004, 279:36171-36174.
38. Yoshida H., et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. J. Biol. Chem. 2005, 280:41111-41121.
39. Jin W., et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 2008, 118:1858-1866.
40. Poser I., et al. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor snail. J. Biol. Chem. 2001, 276:24661-24666.
41. Nieto M.A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3:155-166.
42. Robertson K.D. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002, 21:5361-5379.
43. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
44. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase-activity. Cell 1990, 61:203-212.
45. Smirnoff P., et al. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 1999, 11:255-264.
46. Badia E., et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res. 2000, 60:4130-4138.
47. Kikuno N., et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 2008, 123:552-560.
48. Zhong S., et al. Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007, 26:2621-2634.
49. Reiley W., et al. Regulation of the deubiquitinating enzyme CYLD by I kappa B kinase gamma-dependent phosphorylation. Mol. Cell Biol. 2005, 25:3886-3895.
50. Hutti J.E., et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKK epsilon promotes cell transformation. Mol. Cell 2009, 34:461-472.
51. An J., et al. Inactivation of the CYLD Deubiquitinase by HPV E6 mediates Hypoxia-Induced NF-kappa B Activation. Cancer Cell 2008, 14:394-407.
52. Boyle W.J., et al. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
53. Ang E., et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J. Cell. Physiol. 2009, 220:450-459.
54. Biggs P.J., et al. Familial cylindromatosis (turban tumor syndrome) gene localized to chromosome 16Q12-Q13 - evidence for its role as a tumor-suppressor gene. Nat. Genet. 1995, 11:441-443.
55. Weedon (2002) Skin pathology. Churchill-Livingstone 890-891.
56. Hellerbrand C., et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007, 28:21-27.
57. Annunziata C.M., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
58. Keats J.J., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
59. Sonnichsen B., et al. Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature 2005, 434:462-469.
60. Kamath R.S., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421:231-237.
61. Reiley W.W., et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 2006, 7:411-417.
62. Reiley W.W., et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 2007, 204:1475-1485.
63. Jin W., et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J. Biol. Chem. 2007, 282:15884-15893.
64. Hovelmeyer N., et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J. Exp. Med. 2007, 204:2615-2627.
65. Lim J.H., et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007, 2:e1032.
66. Lim J.H., et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007, 27:349-360.
67. Koga T., et al. Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. J. Biol. Chem. 2008, 283:12546-12554.
68. Zhang M., et al. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J. Biol. Chem. 2008, 283:18621-18626.
69. Friedman C.S., et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 2008, 9:930-936.
70. Stokes A., et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell. Signal. 2006, 18:1584-1594.
71. Dikic I., Crosetto N., Calatroni S., Bernasconi P. Targeting ubiquitin in cancers. Eur J Cancer. 2006, 42:3095-3102.